Shattuck Labs Stock (NASDAQ:STTK)
Previous Close
$3.53
52W Range
$1.33 - $11.76
50D Avg
$3.74
200D Avg
$6.81
Market Cap
$167.05M
Avg Vol (3M)
$412.79K
Beta
1.74
Div Yield
-
STTK Company Profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
STTK Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NRIX | Nurix Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| PRLD | Prelude Therapeutics Incorporated |
| FHTX | Foghorn Therapeutics Inc. |
| STOK | Stoke Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| CSBR | Champions Oncology, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| PRDS | Pardes Biosciences, Inc. |
| ELYM | Eliem Therapeutics, Inc. |